Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16426991 | 0.93 | MAPT (0.54) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL29956372 | 0.91 | POLB (0.44) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL2802409 | 0.91 | POLB (0.44) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL7420999 | 0.86 | HSD17B10 (0.44) | PDE4APDE4BPDE4DKDM4EGAA | |
| SCHEMBL29950801 | 0.86 | HSD17B10 (0.44) | PDE4APDE4BPDE4DKDM4EGAA | |
| SCHEMBL29954452 | 0.85 | SMPD1 (0.48) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL23114 | 0.85 | ENPP2 (0.52) | MAPK1TSHRENPP2ALDH1A1HPGD | |
| SCHEMBL29955098 | 0.84 | ENPP2 (0.44) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL5520238 | 0.81 | APP (0.45) | ENPP2CA1CA2 | |
| SCHEMBL2852131 | 0.81 | TSHR (0.38) | PDE4APDE4BPDE4CPDE4DMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011533-A1 | CARBOXYLIC ACID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海宇道生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11008288-B1 | Methods for preparation of apremilast | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2021-05-18 | — | — | US | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-3027601-A1 | SYK INHIBITORS | Gilead Sciences, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SEPRACOR INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SEPRACOR INC. | 2011-06-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| EP-1919892-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007027527-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027527-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | PDE4A 1481/4885PDE4B 1658/4885PDE4C 1414/4885 |
| US-11008288-B1 | Methods for preparation of apremilast | APRT, ALDH3A1, TPMT | PDE4A 1426/4885PDE4B 1502/4885PDE4C 2909/4885 |
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SI, CYP3A5, CYP2D6 | PDE4A 546/4885PDE4B 303/4885PDE4C 346/4885 |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | SI, CYP3A5, CYP2D6 | PDE4A 546/4885PDE4B 303/4885PDE4C 346/4885 |
| US-20160368918-A1 | SYK INHIBITORS | SYK, BTK, LYN | PDE4A 1476/4885PDE4B 1728/4885PDE4C 1454/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | PDE4A 749/4885PDE4B 1340/4885PDE4C 933/4885 |
| US-10005774-B2 | Syk inhibitors | SYK, BTK, LYN | PDE4A 1476/4885PDE4B 1728/4885PDE4C 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.